RESOURCES FOR YOU

Find more information by visiting SUPPORT ORGANIZATIONS, reading relevant PUBLICATIONS, viewing UPCOMING CONGRESSES, and browsing through our VIDEO LIBRARY.

Publications

View
All
SOT
HCT
Response to Rituximab Induction is a Predictive Marker in B-Cell PTLD

RU Trappe, D Dierickx, H Zimmermann, et al

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-transplant Lymphoproliferative Disorder

Journal of Clinical Oncology
2017;35(5):563-543

Clinical Transplantation article: Post‐transplant Lymphoproliferative Disorders, Epstein‐Barr Virus Infection, and Disease in Solid Organ Transplantation

UD Allen, JK Preiksaitis

Post‐transplant Lymphoproliferative Disorders, Epstein‐Barr Virus Infection, and Disease in Solid Organ Transplantation

Clinical Transplantation
2019;33(9):e13652

H Zimmermann, H Xu, A Barlev, et al

Clinical Outcomes of Solid Organ Transplant Patients with EBV+ PTLD Who Fail First-Line Rituximab or Rituximab Plus Chemotherapy

Poster and abstract presented at: 24th Congress of European Hematology Association Meeting
June 13-16, 2019; Amsterdam, Netherlands

Real-World Outcomes With Rituximab-based Therapy for PTLD

DM Burns, K Clesham, YA Hodgson, et al

Real-World Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant

Transplantation
2020;104(12):25822590

Failure of Rituximab Is Associated With a Poor Outcome in Diffuse Large B Cell Lymphoma-type PTLD

MD Jain, R Lam, Z Liu, et al

Failure of Rituximab Is Associated With a Poor Outcome in Diffuse Large B Cell Lymphoma-type Post-transplant Lymphoproliferative Disorder

British Journal of Haematology
2020;189(1):97-105

Management of EBV infections and PTLD

J Styczynski, W van der Velden, CP Fox, et al

Management of Epstein-Barr Virus Infections and Post-transplant Lymphoproliferative Disorders

Haematologica
2016;101(7):803-811

EBV-associated PTLD Following In Vivo T-cell-depleted Allogeneic Transplantation

CP Fox, D Burns, AN Parker, et al

EBV-associated Post-transplant Lymphoproliferative Disorder Following In Vivo T-cell-depleted Allogeneic Transplantation

Bone Marrow Transplantation
2014;49(2):280-286

Clinical Outcomes of EBV+ PTLD Patients Following HCT Who Fail Rituximab

G Socié, A Pigneux, C Herbaux, et al

Clinical Outcomes of EBV+ PTLD Patients Following HCT Who Fail Rituximab

Abstract

The Role of Epstein-Barr Virus (EBV) in Lymphomagenesis

JI Cohen, CM Bollard, R Khanna, S Pittaluga

Current Understanding of the Role of Epstein-Barr Virus (EBV) in Lymphomagenesis

Leukemia & Lymphoma
2008;49(suppl 1):27-34

Video Library

View
All
Mechanism of Disease
Risk Factors
Disease Management
SOT
HCT
External Expert
Dr Sharif
Risk Factors in Kidney Transplant Recipients
00:55
Dr Parmar
Risk Factors in Lung Transplant Participants
01:15
Dr Lim
Identifying EBV+ PTLD Risk Factors in Heart Transplant Recipients
01:37
Dr Lim
RIS in Heart Transplant
Recipients
01:16
Dr Fox
EBV+ PTLD Pathogenesis
00:54
Dr Fox
Monitoring and Evaluation
of EBV+ PTLD Patients
01:37
Dr Mohty
EBV+ PTLD Pathogenesis
in HCT Patients
01:13
Dr Mohty
EBV+ PTLD Risk Factors
in HCT Patients
01:06
Dr Mohty
Importance of Close Monitoring
of HCT Patients
01:14
Dr Trappe
Heterogeneous Presentation
and Diagnosis of PTLD
00:39
Dr Trappe
Reducing Immunosuppression
in PTLD
00:51
Dr Reshef
Impact of PTLD on Patients
00:52
Dr Reshef
EBV+ PTLD: A “Man-Made” Complication of Transplant
01:15
Dr Reshef
Importance of Increasing
Awareness of PTLD
00:34
EBV+ PTLD
00:47
Latent EBV Infection
01:03
Primary EBV Infection
00:47
EBV Immunosurveillance
01:18